Discuss This Drug

bortezomib

CHEBI:CHEBI_52717

Definition

L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome.

Chemical Information

Molecular Formula
C19H25BN4O4
Molecular Mass
384.23700
Charge
0
SMILES
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChIKey
GXJABQQUPOEUTA-RDJZCZTQSA-N

Alternative Names

  • [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
  • bortezomib
  • bortezomib
  • N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
  • N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
  • PS 341
  • PS-341
  • Velcade

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:52717
DRON_00010000
358258
oboInOwl#hasDbXref
Wikipedia:Bortezomib

Additional References

Wikipedia:Bortezomib

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2693996
manufacturer_name
Shilpa Medicare Limited
package_marketing_start_date
06-JUN-16
unii
69G8BD63PP
spl_set_id
aef02171-bf8a-43ad-b40c-7642623f9802
package_description
10 kg in 1 DRUM (14096-140-02)
route
INTRAVENOUS
package_ndc
82920-006-00
spl_id
4ae077c0-fea9-40d8-9c07-0c5f8dcd69b8
core#notation
CHEBI:52717
active_ingredient_strength
3.5 mg/1.4mL
active_ingredient_name
BORTEZOMIB BORONIC ANHYDRIDE
nui
N0000175075
upc
0367184053018
pharm_class_epc
Proteasome Inhibitor [EPC]
pharm_class
Proteasome Inhibitors [MoA]
pharm_class_moa
Proteasome Inhibitors [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
marketing_category
BULK INGREDIENT
listing_expiration_date
20241231
marketing_start_date
20120121
labeler_name
Shilpa Medicare Limited
application_number
ANDA212958
product_type
HUMAN PRESCRIPTION DRUG
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
358258
generic_name
Bortezomib 3.5mg/vial
brand_name
BORUZU
brand_name_base
BORUZU
oboInOwl#hasDbXref
Wikipedia:Bortezomib
oboInOwl#hasAlternativeId
CHEBI:41143
oboInOwl#id
CHEBI:52717
dosage_form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
product_ndc
67184-0530
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_37670
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
chebi#has_functional_parent
http://purl.obolibrary.org/obo/CHEBI_38267
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect28439
owl#annotatedSource
t245580
has_treatment
http://purl.obolibrary.org/obo/DOID_3721
owl#someValuesFrom
t3038636